The present disclosure relates to the field of endovascular treatment. More particularly, the present invention uses a modified hydrogel intrasaccular occlusion device designed to implement an endovascular treatment to ameliorating or eliminating aneurysm recurrence, which hydrogel may optionally be impregnated with pharmaceutical compounds. The present invention also teaches the use of thin hydrogel coatings to ameliorate endovascular treatment related difficulties.

An intraluminal prosthesis includes an outer three-dimensional (3D) anti-migration structure that is attached to the outer wall of a fully covered or partially covered stent to prevent migration and still allow stent removal at a later period of time. A method of manufacturing the intraluminal prosthesis includes attaching the anti-migration structure by usage of a polymer such as polyurethane.

Disclosed are a nanofiber mat, a manufacturing method thereof, and applications thereof as a mat for cell culturing or as a barrier membrane for guided bone regeneration (GBR). The nanofiber layer includes a nanofiber layer and a reinforcement pattern that is disposed on the nanofiber layer and adhesively connected with the nanofiber layer. The nanofiber layer and the reinforcement pattern are combined with each other by at least one of the melting-solidification of at least a part of the nanofiber layer together with the reinforcement pattern, the dissolution-solidification of the same, and the penetration of a part of the reinforcement pattern into the nanofiber layer, followed by solidification.

The present Invention' relates to a method of preparing reduced grapheme oxide, Incorporation of the adduced graphene oxide into polyisoprene latex to provide a polyisoprene latex graphene composite and elastomerk articles prepared using the polyisoprene latex-graphene composite. In particular, the reduction of-graphene oxide is accomplished without the use of strong reducing agents and organic solvents and incorporation of die reduced graphene oxide into polyisoprene latex Is accomplished using room temperature latex mixing method or hot maturation. The resultant composite exhibits good colloid stability and polyisoprene latex films produced from the composite exhibit good mechanical properties with improved ageing resistance.

The present Invention' relates to a method of preparing reduced grapheme oxide, Incorporation of the adduced graphene oxide into polyisoprene latex to provide a polyisoprene latex graphene composite and elastomerk articles prepared using the polyisoprene latex-graphene composite. In particular, the reduction of-graphene oxide is accomplished without the use of strong reducing agents and organic solvents and incorporation of die reduced graphene oxide into polyisoprene latex Is accomplished using room temperature latex mixing method or hot maturation. The resultant composite exhibits good colloid stability and polyisoprene latex films produced from the composite exhibit good mechanical properties with improved ageing resistance.

A high-strength medical fiber composite material includes a sodium alginate hydrogel matrix and a fiber framework. The fiber framework is completely embedded in the sodium alginate hydrogel matrix and formed by compounding supporting layer fibers and reinforcing layer fibers. The reinforcing layer fibers are located above the supporting layer fibers. The reinforcing layer fibers and the supporting layer fibers are orthogonal to each other. According to the high-strength medical fiber composite material prepared in the present invention, the stiffness is improved by 3-4 orders of magnitude, the tensile strength is improved by 2-3 orders of magnitude, and the high-strength medical fiber composite material has high biocompatibility and safety and a great application prospect.

A material for adhesion prevention can be adhered to biological tissue with certainty and has improved tissue adhesiveness and biodegradability. Such material for adhesion prevention is composed of: a 1- to 1,000-m-thick water-soluble support layer comprising a water-soluble polymer; and a 1- to 1,000-m-thick adhesion prevention layer comprising a biodegradable polymer. The biodegradable polymer has a structure in which a branched polyalkylene glycol comprising 3 to 8 terminal hydroxyl groups per molecule is bound to a polyhydroxy alkanoic acid, and a mass ratio of the branched polyalkylene glycol relative to the total mass is 1% to 30%.

A treatment of a medical difficulty associated with the formation or presence of a blood clot in a blood vessel, commonly known as thrombectomy. Said treatment may be achieved by introducing and positioning through a single lumen a device capable of macerating, irrigating and aspirating as well as supporting structures proximal to the distal end of said device. Said device is introduced via a blood vessel, and deployed at a treatment site. The macerator is then operated to dislocate thrombus, clot, or other occlusive materials at the target site, the irrigating element is then operated to continue to dislocate thrombus, clot, or other occlusive materials at the target site, and the aspirating element is used to collect and remove the disruptive materials from the target site.

A treatment of a medical difficulty associated with the formation or presence of a blood clot in a blood vessel, commonly known as thrombectomy. Said treatment may be achieved by introducing and positioning through a single lumen a device capable of macerating, irrigating and aspirating as well as supporting structures proximal to the distal end of said device. Said device is introduced via a blood vessel, and deployed at a treatment site. The macerator is then operated to dislocate thrombus, clot, or other occlusive materials at the target site, the irrigating element is then operated to continue to dislocate thrombus, clot, or other occlusive materials at the target site, and the aspirating element is used to collect and remove the disruptive materials from the target site.

A treatment of a medical difficulty associated with the formation or presence of a blood clot in a blood vessel, commonly known as thrombectomy. Said treatment may be achieved by introducing and positioning through a single lumen a device capable of macerating, irrigating and aspirating as well as supporting structures proximal to the distal end of said device. Said device is introduced via a blood vessel, and deployed at a treatment site. The macerator is then operated to dislocate thrombus, clot, or other occlusive materials at the target site, the irrigating element is then operated to continue to dislocate thrombus, clot, or other occlusive materials at the target site, and the aspirating element is used to collect and remove the disruptive materials from the target site.